References
- Andersson KE. 2018. PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol. 175(13):2554–2565.
- Christensen BS, Gronbaek M, Osler M, Pedersen BV, Graugaard C, Frisch M. 2011. Associations between physical and mental health problems and sexual dysfunctions in sexually active Danes. J Sex Med. 8(7):1890–1902.
- Corona G, Rastrelli G, Burri A, Jannini EA, Maggi M. 2016. The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. Expert Opin Drug Saf. 15(2):237–247.
- Dalvie D. 2000. Recent advances in the applications of radioisotopes in drug metabolism, toxicology and pharmacokinetics. Curr Pharm Des. 6(10):1009–1028.
- Gao ZW, Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, Chen XY, Li XN, Zhong DF. 2015. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. Acta Pharmacol Sin. 36(12):1528–1536.
- Grant P, Jackson G, Baig I, Quin J. 2013. Erectile dysfunction in general medicine. Clin Med. 13(2):136–140.
- Hyland R, Roe EG, Jones BC, Smith DA. 2001. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 51(3):239–248.
- Isin EM, Elmore CS, Nilsson GN, Thompson RA, Weidolf L. 2012. Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies. Chem Res Toxicol. 25(3):532–542.
- Jung J, Choi S, Cho SH, Ghim J-L, Hwang A, Kim U, Kim BS, Koguchi A, Miyoshi S, Okabe H, others, et al. 2010. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther. 32(6):1178–1187. and
- Lappin G. 2015. A historical perspective on radioisotopic tracers in metabolism and biochemistry. Bioanalysis. 7(5):531–540.
- McCullough AR. 2002. Four-year review of sildenafil citrate. Rev Urol. 4(Suppl 3):S26–S38.
- Nassar AE, Bjorge SM, Lee DY. 2003. On-line liquid chromatography-accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identification in drug discovery and development. Anal Chem. 75(4):785–790.
- Penner N, Xu L, Prakash C. 2012. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol. 25(3):513–531.
- Roffey SJ, Obach RS, Gedge JI, Smith DA. 2007. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev. 39(1):17–43.
- Scaglione F, Donde S, Hassan TA, Jannini EA. 2017. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: pharmacology and clinical impact of the sildenafil citrate orodispersible tablet formulation. Clin Ther. 39(2):370–377.
- Tian QQ, Zhu YT, Diao XX, Zhang XL, Xu YC, Jiang XR, Shen JS, Wang Z, Zhong DF. 2021. Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor. Acta Pharmacol Sin. 42(3):482–490.
- Uckert S, Kuczyk MA, Oelke M. 2013. Phosphodiesterase inhibitors in clinical urology. Expert Rev Clin Pharmacol. 6(3):323–332.
- Wang Z, Zhu D, Yang X, Li J, Jiang X, Tian G, Terrett NK, Jin J, Wu H, He Q, others, et al. 2013. The selectivity and potency of the new PDE5 inhibitor TPN729MA. J Sex Med. 10(11):2790–2797.
- Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. 2000. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 28(4):392–397.
- Zhu Y. 2017. Study on the metabolism, pharmacokinetics, drug-drug interaction, and multidrug resistance revesal effect of TPN729. Beijing: Chinese Academy of Science University.
- Zhu Y, Li L, Deng P, Chen X, Zhong D. 2016. Characterization of TPN729 metabolites in humans using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal. 117:217–226.